The randomized, double- blind, placebo-controlled, multi-center research study will work with 150 adult patients all of whom are currently on maximal medical therapy. Additionally, these patients are not suitable candidates for the typical procedures to improve blood flow to the heart like stents, angioplasty, or bypass surgery.

"Baxter's sponsorship of this trial is consistent with our mission to be a leader in providing innovative life-saving therapies, and to pursue new opportunities where our technology can potentially help save and sustain lives," said Norbert Riedel, Ph.D., Baxter's chief scientific officer. "We're excited and privileged to work with world-class researchers in the field of cardiovascular disease to potentially satisfy this unmet medical need.

Read More at Yahoo - Baxter Commences First-Of-Its-Kind, Phase II Adult Stem Cell Trial in U.S. in Patients With Severe Coronary Artery Disease